PBMs Sue To Block FTC's In-House Insulin Pricing Case

By Matthew Perlman · November 20, 2024, 4:59 PM EST

Caremark Rx, Express Scripts and OptumRx have lodged a constitutional challenge of the Federal Trade Commission's in-house case accusing the pharmacy benefits managers of artificially inflating insulin prices through unfair rebate...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Express Scripts, Inc. et al v. Federal Trade Commission et al

Case Number

Court

Missouri Eastern

Nature of Suit

Other Statutory Actions

Date Filed

November 19, 2024

Recent Articles By Matthew

November 07, 2024
Teva Can't End Inhaler Antitrust Suit But Gets Claim Nixed
November 01, 2024
Health Data Co. Urges 4th Circ. To Keep Access Open
October 31, 2024
Drug Cos. To Pay $49M For State-Led Generic Pricing Claims
October 30, 2024
Ohio PBM Case Will Wait For High Court Ruling
October 24, 2024
PBMs Want Separate FTC Hearings Over Insulin Prices
October 21, 2024
NC Justices Revive Challenge To Hospital Competition Law
October 15, 2024
FTC Wants More Info On $1.36B Home Healthcare Deal
October 07, 2024
Justices Won't Hear Shkreli's Bid To Undo $64M Disgorgement
September 23, 2024
Medical Records Co. Accused Of Blocking Data Access
September 20, 2024
FTC Accuses Drug Middlemen Of Raising Insulin Prices